Related Experiment Video
Updated: Feb 24, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Ficolin-2 triggers antitumor effect by activating macrophages and CD8+ T cells
Quanquan Ding1, Yanying Shen1, Dongqing Li2
1State Key Laboratory of Virology and Medical Research Institute, Hubei Province Key Laboratory of Allergy and Immunology and Department of Immunology, Wuhan University School of Basic Medical Sciences, Wuhan 430071, PR China.
Abstract:
Ficolin-2 is an important serum complement lectin. Here, we describe novel findings indicating that serum ficolin-2 concentrations in multiple tumor patients are significantly lower than those in healthy donors. Administration of exogenous ficolin-2 or ficolin-A (a ficolin-2-like molecule in mouse), with only once, could remarkably inhibit the tumor cells growth in murine tumor models via early macrophages, dendritic cells (DCs) and CD8+ T cells, but not CD4+ T cells. Ficolin-A (FCN-A) knockout (KO) mice exhibits significantly increased tumor cell growth. Ficolin-2 induces macrophage activation, promotes M1 polarization and facilitates proliferation and antigen-specific cytotoxicity of CD8+ T cells. Ficolin-2 binds to Toll-like receptor 4 (TLR4) on macrophages and DCs and promotes their antigen-presenting abilities to CD8+ T cells. Our findings provide a new therapeutic strategy for tumors based on the triggering of immune-mediated antitumor effect by ficolin-2.
Insights
Serum ficolin-2 levels are lower in cancer patients. Supplementing ficolin-2 inhibits tumor growth by activating immune cells like macrophages and CD8+ T cells, suggesting a new cancer therapy.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Ficolin-2 is a serum complement lectin.
- Lower serum ficolin-2 concentrations are observed in patients with multiple tumors compared to healthy individuals.
Purpose of the Study:
- To investigate the role of ficolin-2 in tumor growth.
- To explore ficolin-2 as a potential therapeutic agent for cancer.
Main Methods:
- Administration of exogenous ficolin-2 or ficolin-A in murine tumor models.
- Analysis of immune cell responses (macrophages, dendritic cells, CD8+ T cells, CD4+ T cells).
- Assessment of tumor cell growth in wild-type and Ficolin-A knockout mice.
- Investigation of ficolin-2 binding to Toll-like receptor 4 (TLR4).
Main Results:
- Single administration of ficolin-2 or ficolin-A significantly inhibited tumor cell growth in murine models.
- Ficolin-A knockout mice showed increased tumor cell growth.
- Ficolin-2 activated macrophages, promoted M1 polarization, and enhanced CD8+ T cell proliferation and cytotoxicity.
- Ficolin-2 binds to TLR4 on macrophages and dendritic cells, improving their antigen-presenting capabilities.
Conclusions:
- Ficolin-2 exhibits potent antitumor effects by modulating the immune system.
- Ficolin-2 enhances innate and adaptive immune responses against tumors.
- Ficolin-2 represents a promising therapeutic strategy for cancer by leveraging immune-mediated antitumor effects.
Related Concept Videos
Tumor Immunotherapy
Drugs that Stabilize Microtubules
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The Tumor Microenvironment
Regulation of Hematopoietic Stem Cells
The Extrinsic Apoptotic Pathway

